COMP <GO>
SER vs ANVS // EV/EBITDA & P/E VALUATION
Serina Therapeutics Inc. (NYSE) VS. Annovis Bio Inc. (NYSE) • 15-METRIC TALLY: SER 3
— ANVS 0
■ METRIC PARITY
LAST: $1.85 (-4.64%) • MKT CAP: $49.3M
valuation
—
LAST: $1.08 (-4.42%) • MKT CAP: $48.2M
valuation
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (SER VS. ANVS)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | SER | ANVS | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | -35.00% | 0.00 | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | — | — | TIE | /fcf-yield <GO> |
| Operating Margin | -60.00% | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | -60.00% | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | 132.10% | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 3/9 | 1/9 | +2.00 | SER | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 52.3 | 51.7 | +0.60 | SER | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $49.3M | $48.2M | $1.0M | SER | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | SER REV | ANVS REV | SER GROSS % | ANVS GROSS % | SER FCF | ANVS FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $130.0K | $83.1M | — | — | -$18.0M | -$25.6M |
| FY 2024 | $56.0K | $74.7M | — | — | -$17.2M | -$21.9M |
| FY 2023 | $3.2M | $126.1M | — | — | -$2.5M | -$40.0M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
SER // BETA —
ANVS // BETA —